Susan Whoriskey Biotechnology Entrepreneur International Advisory Panel Member C-TRIC
Dr. Whoriskey has been a member of the founding executive teams of both Momenta Pharmaceuticals. Inc. (MNTA) and Cubist Pharmaceuticals, Inc. (CBST). These successful companies achieved significant value creation by defining and employing cutting edge science and paradigm shifting business strategies towards the goal of bringing important therapeutics to the market place.
As a member of the executive teams she played key roles in managing these companies to grow from: seed venture capital financing through IPO and follow-on financings, small founding teams to fully operational businesses, technology start-up platforms to submitting marketing applications for approval of drugs at the FDA (both approved and pending).
(2002–2007). Vice President, Momenta Pharmaceuticals. Dr. Whoriskey joined Momenta with the scientific founder as part of the founding executive team. The team defined and implemented a unique biotechnology business strategy to generate near term revenue potential in order to fund longer term innovation by simultaneously applying its technology to complex generic product opportunities and the development of novel therapeutics.
In her capacity as an executive team member she helped manage: (i) execution of license agreements with key academic institutions such as MIT to acquire an extensive intellectual property portfolio, (ii) raising of significant capital through private equity, IPO, follow-on financing and collaborations, (ii) execution of strategic collaborations with the Sandoz division of Novartis, and (viii) filing of applications at the FDA for development of novel products and marketing approval of a complex generic drug product.
(2001-2002). Dr. Whoriskey was a biotechnology consultant to Polaris Venture Partners, a venture capital firm, where she conducted due diligence on opportunities and implemented the business and recruiting operations of Momenta upon Polaris’ decision to seed fund the company.
(1993-2001). Dr. Whoriskey held various management positions at Cubist Pharmaceuticals, Inc., a biopharmaceutical company focused on antibiotic development. Dr. Whoriskey joined the company at its earliest stage when it had a promising technology platform for antibiotic drug discovery and modest funding. She helped recruit management team members and the scientific staff, was involved in multiple private and public equity fundraising rounds, including taking the company public in 1996, and was involved in negotiating numerous collaborations with academic, biotech and major pharmaceutical companies including Novartis, Pfizer, Merck and Bristol Myers Squibb. She also had a role in overseeing the company’s intellectual property estate. Dr. Whoriskey was involved in the in-licensing of the company’s flagship product from Eli Lilly, Cubicin, shifting the prevailing business paradigm of the time away from biotechnology companies licensing out their products to internal business building by licensing from big pharma. The company went on to develop this life-saving novel antibiotic active against drug resistant bacteria and has obtained approval for multiple indications of the product in numerous countries.
(1989-1993). Prior to Cubist, Dr. Whoriskey was a Fellow in the Department of Molecular Genetics at Harvard Medical School and the Department of Molecular Biology at Massachusetts General Hospital.
Dr. Whoriskey earned her Ph.D. in Molecular Biology from the Molecular Biology Institute-University of California, Los Angeles and a Bachelor of Science in Microbiology from the University of Massachusetts-Amherst.